SABCS 2022 Meeting News Welcome Edition - 3

3
PRESENTER
PROFILE:
Sheila A. Stewart, PhD
Gerty Cori Professor and Vice Chair,
Department of Cell Biology & Physiology
Associate Director for Basic
Sciences, Siteman Cancer Center
Washington University School
of Medicine, St. Louis, MO
BASIC SCIENCE WORKSHOP
Tuesday, 8:00 am - 9:45 am CT
Stars at Night Ballroom 3&4
PRESENTATION: Therapy-induced
senescence: Friend or foe?
Q: What is your presentation about?
A: We are interested in how the metastatic
tumor microenvironment (NOT tumor cells)
impact tumor progression and remodel the
immune response. We found that the p38MAPK
pathway in stromal cells contributes to tumor
progression. Thus, we embarked on trying to
understand how the microenvironment impacts
progression and to use that information to
design preclinical models to limit metastatic
breast cancer progression. In doing so, we
identified a combination of p38 inhibition and
T cell activation through the use of an agonist
against OX40. This combination approach, in the
presence of an experimental CD8 T cell antigen
led to a cure and durable immunologic memory.
Given that we see tumor microenvironmental
signatures that are similar in human metastatic
lesions, we suggest that this approach could
have an impact in human disease.
Q: What makes this topic important
in 2022?
A: We have known for years that targeted
therapies require a detailed understanding of
the tumor microenvironment, and our approach
provides insight into this important component of
breast cancer. Our data argue that p38 inhibition
is as potent as chemotherapy as a single agent
with significantly fewer side effects. However,
when combined with immunotherapy, we observe
a significant reduction in tumor progression.
We think this approach, detailing the tumor
microenvironment, will be important to the future
design of effective therapies.
Q: How/why did you become involved
with this area of breast cancer
research?
A: I have been interested in how nontumor
cells impact tumorigenesis for a long time, as I
feel that a coordinated attack of cancer (tumor
targeted modalities in combination with stromal
and immune modulatory agents) will eventually
result in durable responses. Given metastatic
disease is what remains intractable, I wanted to
specifically understand the metastatic stromal
compartment. 
TUESDAY, DECEMBER 6
SCHEDULE-AT-A-GLANCE
*As of November 18, 2022 | **All times are CENTRAL Time
8:00 am - 9:45 am CT
Clinical Research Workshop
Stars at Night Ballroom 1&2
Basic Science Workshop
Stars at Night Ballroom 3&4
10:00 am - 12:00 pm CT
EDUCATIONAL SESSION
BLOCK #1
Living with Metastatic Breast
Cancer
Stars at Night Ballroom 3&4
Local Therapy - Best Breast
Practice
Hemisfair Ballroom 1&2
New Agents Targeting HRD in
Breast Cancer
Hemisfair Ballroom 3
Predictive Value of Treatment
Response and Residual
Disease After Neoadjuvant
Therapy
Stars at Night Ballroom 1&2
12:00 pm - 2:00 pm CT
SPECIAL SESSION:
Big Data and Health Equity
Stars at Night Ballroom 1&2
Overcoming the Big Obstacles
to Find Solutions for Breast
Cancer
Hall 3
2:00 pm - 5:00 pm CT
GENERAL SESSION #1
Hall 3
5:00 pm - 6:15 pm CT
POSTER SESSION #1
Hall 1
SPOTLIGHT POSTER
DISCUSSION SESSION #1:
Racial Outcomes and Disparities
Hemisfair Ballroom 1&2
SPOTLIGHT POSTER
DISCUSSION SESSION #2:
Tumor Immunology and Novel
Immune Therapy Strategies
Stars at Night Ballroom 1&2
SPOTLIGHT POSTER
DISCUSSION SESSION #3:
New Radiation Techniques
Stars at Night Ballroom 3&4
7:00 pm - 10:00 pm CT
Open Satellite Events
GENERAL SESSION #1
ABSTRACT PRESENTATIONS
Tuesday, December 6 | 2:00 pm - 5:00 pm CT | Hall 3
2:00 pm - 2:15 pm CT
GS1-01: Race and clinical outcomes in the
RxPONDER trial (SWOG S1007)
2:15 pm - 2:30 pm CT
GS1-02: Racial disparity in tumor microenvironment
and outcomes in residual breast cancer treated with
neoadjuvant chemotherapy
2:30 pm - 2:45 pm CT
Discussant for GS1-01 and GS1-02
2:45 pm - 3:00 pm CT
GS1-04: Patient-reported cognitive impairment in
women participating in the RxPONDER trial (SWOG
S1007) by menopausal status
3:00 pm - 3:15 pm CT
GS1-05: Trial Assigning Individualized Options for
Treatment (TAILORx): An update including 12-year
event rates
3:15 pm - 3:30 pm CT
GS1-06: Evaluation of the Breast Cancer Index in
premenopausal women with early-stage HR+ breast
cancer in the SOFT trial
3:30 pm - 3:45 pm CT
GS1-07: Results from a phase III randomized,
placebo-controlled clinical trial evaluating
adjuvant endocrine therapy +/- 1 year of
everolimus in patients with high-risk hormone
receptor-positive, HER2-negative breast cancer:
SWOG S1207
3:45 pm - 4:00 pm CT
Discussant for GS1-06 and GS1-07
4:00 pm - 4:15 pm CT
GS1-09: Abemaciclib plus endocrine therapy for
HR+, HER2-, node-positive, high-risk early breast
cancer: results from a pre-planned monarchE overall
survival interim analysis, including 4-year efficacy
outcomes
4:15 pm - 4:30 pm CT
GS1-10: Primary results from the randomized
Phase II RIGHT Choice trial of premenopausal
patients with aggressive HR+/HER2- advanced
breast cancer treated with ribociclib + endocrine
therapy vs physician's choice combination
chemotherapy
WELCOME EDITION | SABCSMEETINGNEWS . ORG
SABCS 2022 Meeting News Welcome Edition

Table of Contents for the Digital Edition of SABCS 2022 Meeting News Welcome Edition
